A retrospective single-center study analyzed the safety and efficacy of ICI readministration after the onset of irAEs in NSCLC patients treated with anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies in combination or as a monotherapy [49]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.